NCT03901105 - Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

April 28, 2019

Study Completion Date

April 28, 2019

Conditions

Alzheimer Disease

Interventions

DRUG

flortaucipir F18

No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES

PROCEDURE

Brain PET Scan

positron emission tomography (PET) scan of the brain

Trial Locations (1)

19104

American College of Radiology, Philadelphia